Abstract

Gastric inhibitory polypeptide (GIP, glucose-dependent insulinotropic polypeptide) is expressed by intestinal K cells to regulate glucose-induced insulin secretion. The impact of Roux-en Y bypass (RYGB) surgery on blood GIP is highly contraversial. This study was conducted to address the mechanism of controversy. GIP mRNA was examined in the intestine, and serum GIP was determined using Luminex and ELISA in diet-induced obese (DIO) mice. The assays were conducted in RYGB mice in fasting and fed conditions. Food preference, weight loss and insulin sensitivity were monitored in RYGB mice. In DIO mice, GIP mRNA was increased by 80% in all sections of the small intestine over the lean control. The increase was observed in both fasting and fed conditions. After RYGB surgery, the food-induced GIP expression was selectively reduced in the Roux-limb, but not in the biliopancreatic and common limbs of intestine in fed condition. Lack of stimulation by glucose or cholesterol contributed to the reduction. Jejunal mucosa of Roux-limb exhibited hypertrophy, but villous surface was decreased by the undigested food. Serum GIP (total) was significantly higher in the fasting condition, but not in the fed condition due to attenuated GIP response to food intake in RYGB mice. The GIP alteration was associated with chow diet preference, sustained weight loss and insulin sensitization in RYGB mice. RYGB increased serum GIP in the fasting, but not in the fed conditions. The loss of food-induced GIP response in Roux-limb of intestine likely contributes to the attenuated serum GIP response to feeding.

Highlights

  • Roux-en-Y gastric bypass surgery (RYGB) is a powerful therapy for obesity and type 2 diabetes [1, 2]

  • The results suggest that intestinal GIP mRNA was increased by high fat diet (HFD) and reduced in the Roux-limb by RYGB surgery

  • We examined GIP mRNA in the intestine to understand serum GIP response to RYGB surgery in a mouse RYGB model

Read more

Summary

Introduction

Roux-en-Y gastric bypass surgery (RYGB) is a powerful therapy for obesity and type 2 diabetes [1, 2]. In addition to the anatomical alterations, changes in gut hormone secretion have been suggested for the negative energy balance These hormones include glucagon-like peptide 1 (GLP-1) [8,9,10], peptide YY (PYY), GIP (gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide), cholecystokinin (CCK), ghrelin and amylin [11, 12]. Studies from this and other groups suggest that PYY [13] and leptin [14], but not GLP-1 [15, 16], may contribute to the metabolic effects of RYGB.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.